COMMUNIQUÉS West-GlobeNewswire

Supernus Announces Fourth Quarter and Full Year 2024 Financial Results
25/02/2025
Fourth quarter 2024 net sales of Qelbree ® increased 60% to $74.4 million, compared to the same period in 2023. Full year 2024 net sales of Qelbree increased 72% to $241.3 million, compared to full year 2023. Fourth [...]
Xenon to Present at the 45th Annual TD Cowen Healthcare Conference
25/02/2025
VANCOUVER, British Columbia and BOSTON, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering [...]
Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
25/02/2025
-- Completed Successful VAX-31 Phase 2 Adult Program; Company Remains on Track to Initiate VAX-31 Adult Phase 3 Pivotal, Non-Inferiority Study by Mid-2025 and Announce Topline Safety, Tolerability and Immunogenicity [...]
DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress
25/02/2025
Châtillon, France, February 25, 2025 DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage [...]
DBV Technologies participera au prochain congrès conjoint AAAAI/WAO
25/02/2025
Châtillon, France, le 25 février (22 :30 CEST) 2025 DBV Technologies participera au prochain congrès conjoint AAAAI/WAO DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), une société [...]
Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I Disorder
25/02/2025
UZEDY is currently approved in the US as a subcutaneous long-acting injectable (LAI) for use every one or two months for the treatment of schizophrenia in adults 1 LAI treatment options may help address unmet needs of [...]
Arcutis Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
25/02/2025
WESTLAKE VILLAGE, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Q4 2024 net product revenue for ZORYVE® (roflumilast) was $69.4 million, a 413% increase compared to Q4 of 2023 and a 55% increase compared to Q3 of 2024; [...]
Merus annonce sa participation aux prochaines journées Investisseurs
25/02/2025
UTRECHT, Pays-Bas et CAMBRIDGE, État du Massachusetts, 25 févr. 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS), une société d’oncologie au stade clinique développant des anticorps multispécifiques de pleine [...]
Lipozem Under Review: The Truth About Lipozem and Triple-BHB Power for Weight Loss
25/02/2025
LAKELAND, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Lipozem is a groundbreaking solution designed to support individuals in shedding stubborn weight without resorting to exhaustive diets or intense workouts. In today’s [...]
Capital Increase in Genmab as a Result of Employee Warrant Exercise
25/02/2025
Company Announcement COPENHAGEN, Denmark; February 25, 2025 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 10,058 shares as a consequence of the exercise of employee warrants. The increase is effected [...]
GT Biopharma Announces Exercise of Warrants
25/02/2025
SAN FRANCISCO, CALIFORNIA, Feb. 25, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company [...]
AscellaHealth Expands Leadership Team to Accelerate Growth, Strengthen Operations and Advance Patient-Centric Solutions
25/02/2025
BERWYN, Pa., Feb. 25, 2025 (GLOBE NEWSWIRE) -- AscellaHealth , a global partner delivering customizable solutions to support the specialty pharmaceutical industry, today announced the appointment of two senior leaders: [...]
Bondholders approve amended terms of the 2025 convertible bonds
25/02/2025
Ad hoc announcement pursuant to Art. 53 LR The proposed amendments to the terms of the 2025 convertible bond have been approved by the bondholders and will become binding and effective upon approval by the higher [...]
IBA and Jabil sign contract to install a Be-Wide X-ray solution in Mississippi, USA
25/02/2025
Louvain-la-Neuve, Belgium, February 25, 2025 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and electron beam and X-ray solutions for industrial irradiation, and Jabil [...]
IBA et Jabil signent un contrat pour l'installation d'une solution Be-Wide X-ray dans le Mississippi, aux États-Unis
25/02/2025
Louvain-la-Neuve, Belgique, le 25 février 2025 - IBA (Ion Beam Applications S.A.), le leader mondial des technologies d’accélération de particules et des solutions d'irradiation industrielle par faisceau d'électrons et [...]
Nanox to Present New Clinical Data on Nanox.ARC Advanced 3D Digital Tomosynthesis Imaging System at ECR 2025
25/02/2025
In a clinical study, it was found that the Nanox.ARC digital tomosynthesis enhanced musculoskeletal imaging, can improve the sensitivity and specificity of conventional radiography. In addition, can improve cast and [...]
UPMC, Advocate Health and Xealth Executives to Speak at HIMSS25, Revealing Ways to Strategically Roll Out and Measure Digital Health
25/02/2025
LAS VEGAS, Feb. 25, 2025 (GLOBE NEWSWIRE) -- HIMSS -- Xealth , the leader in enabling digital health at scale, today announced that CEO and Co-founder Mike McSherry will join UPMC CMIO Dr. Robert Bart, and separately [...]
Biologic Pharmamedical Expands Manufacturing Flexibility to Meet Customer Demand
25/02/2025
VANCOUVER, British Columbia, Feb. 25, 2025 (GLOBE NEWSWIRE) -- For years, Biologic Pharmamedical has been steadfast in its commitment to scientific excellence, patent security, and the highest quality control in [...]
UPDATE – Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference
25/02/2025
CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics , Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for [...]

Pages